# Simulations Plus, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Simulations Plus, Inc.). ## Overview Simulations Plus, Inc. develops software and consulting services used in biopharma research, drug development, clinical trials, and commercialization. The company is based in the United States and operates through wholly owned subsidiaries, serving customers globally across the drug development lifecycle. ## Products & services • Biosimulation software for drug discovery and development • Modeling and simulation consulting services • AI-augmented scientific insights and platform customization • Clinical trial operations and commercialization support • Software and services for PK/PD, PBPK, MIDD, QSP, and AIDD - **Software** (58%) — Scientific software platforms used for biosimulation, modeling, and drug development workflows. - **Services** (42%) — Consulting, customization, and expert support for drug discovery and development programs. - Biosimulation software for drug discovery and development - Modeling and simulation consulting services - AI-augmented scientific insights and platform customization - Clinical trial operations and commercialization support - Software and services for PK/PD, PBPK, MIDD, QSP, and AIDD ## Customers Customers are primarily biopharma organizations that use modeling and simulation to improve drug discovery, development, and commercialization decisions. The company also serves biotechnology, agrotechnology, and cosmetics companies, along with universities, hospitals, and government research organizations. Buyers typically seek specialized scientific expertise, software tools, or outsourced capacity that they do not have in-house. - **Pharmaceutical companies** (primary) — Buy software and consulting to support discovery, clinical development, and commercialization decisions. - **Biotechnology companies** (primary) — Use the platform and expert services to supplement limited internal modeling resources. - **Research institutions and government organizations** (secondary) — Use the software for scientific research, training, and applied drug-development studies. - **Non-pharma industries** (emerging) — Agrotechnology and cosmetics customers use selected tools for modeling and scientific analysis. - Pharmaceutical companies using MIDD tools to improve R&D decisions - Biotechnology firms needing specialized modeling and simulation support - Agrotechnology and cosmetics companies using scientific software - Universities, hospitals, and government research organizations - Clients outsourcing PK/PD, PBPK, QSP, and related analyses ## Geography The company markets its software and services globally, with sales and marketing activity spanning scientific meetings, trade shows, seminars, online channels, and direct outreach. It also uses independent distributors in Japan, China, India, South Korea, and Brazil, which extends reach in key international markets. Geography matters because adoption depends on relationships with research communities and regulatory environments across major pharma hubs. - United States is the corporate base and a major operating market - Global commercial reach through scientific meetings and direct sales - Independent distributors in Japan, China, India, South Korea, and Brazil - International pharma hubs matter because customers are research-intensive - Regulatory and scientific adoption varies by region and affects demand ## Strategy The company is focused on expanding use of its software and services across the full drug development lifecycle, from early discovery through commercialization. It is also pursuing an account-based solution-selling model that emphasizes solving client pain points rather than selling discrete products. Strategic acquisitions, partnerships, and deeper penetration of existing accounts are intended to broaden the platform and increase recurring engagement. - **Expand existing client relationships** (short-term) — Deeper adoption increases software and services revenue per account and strengthens retention. - **Account-based solution selling** (short-term) — Selling integrated solutions improves relevance to client pain points and supports scalable growth. - **Strategic acquisitions and partnerships** (medium-term) — External growth can add capabilities, customers, and market access in adjacent areas. - Expand penetration within existing biopharma accounts - Sell integrated solutions across the drug development lifecycle - Use account-based selling to align offerings with client pain points - Pursue acquisitions and partnerships to broaden capabilities - Grow adoption of AI-augmented modeling and simulation tools ## Risks Demand depends on continued acceptance of model-informed drug development, regulatory support, and customers' willingness to outsource specialized work. The business also faces competition from software vendors, CROs, consulting firms, and internal teams at large pharma companies, while AI adoption introduces reputational, legal, and cybersecurity risks. Because revenue is tied to scientific adoption and client budgets, market penetration and execution risk are central to the model. - **Limited adoption of model-informed drug development** [high] — If regulators or academic institutions resist these methods, demand for the company's tools and services can weaken. - **Competitive pressure from larger and adjacent providers** [high] — Competitors include established software firms, CROs, consulting groups, and in-house pharma teams with greater resources. - **AI and machine learning deployment risk** [medium] — Flawed models, poor datasets, or harmful outputs could damage reputation and create legal or regulatory exposure. - **Dependence on client budgets and outsourcing decisions** [high] — Customers may reduce spending or bring work in-house, lowering software and services demand. - Customer adoption of MIDD and biosimulation can slow demand - Competition includes software vendors, CROs, and in-house pharma teams - AI and machine learning use can create reputational and legal risk - International distributor network adds execution and channel risk - Acquisitions can create integration and retention challenges ## Accounting Revenue recognition is a key judgment area because the company sells both software licenses and consulting services, including customized platform work. Management must estimate consulting hours and allocate transaction prices across performance obligations, which affects the timing of revenue recognition. Capitalized software development costs, goodwill and intangible assets from acquisitions, and stock-based compensation are also important because they can materially affect reported earnings and balance sheet values. - **Revenue recognition** — Affects quarterly revenue mix and comparability - **Capitalized software development costs** — Impacts operating expense and intangible assets - **Goodwill and intangible assets** — Can create non-cash impairment charges - **Stock-based compensation** — Affects reported profitability and dilution - Software licenses and consulting services have different revenue timing - Consulting contracts require estimates of hours and costs to complete - Custom platform work can involve multiple performance obligations - Capitalized software development costs affect operating expense timing - Goodwill and intangibles from acquisitions can require impairment testing --- *Last updated: 2026-04-29T04:58:43.862436+00:00*